Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The CooperCOO +1.41%86 Revenue per Share is $21.43 as of Apr. 2026. GuruFocus rates COO with a GF Score™ of 86/100 and a GF Value™ of $102.02 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 757 Medical Devices & Instruments companies, The Cooper ranks better than 60.9% on this metric.
The Cooper's revenue per share for the
three
months ended in Apr. 2026 was $5.55.
The Cooper's revenue per share for the trailing twelve months (TTM) ended in Apr. 2026 was $21.43.
Good Sign:
The Cooper Companies Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue Per Share Growth Rate of The Cooper was 7.90% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 7.10% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 10.50% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 8.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for The Cooper's Revenue per Share or its related term are showing as below:
COO'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -62.6 Med: 8.2 Max: 30.8
Current: 7.1
During the past 13 years, The Cooper's highest 3-Year average Revenue Per Share Growth Rate was 30.80% per year. The lowest was -62.60% per year. And the median was 8.20% per year.
COO's 3-Year Revenue Growth Rate is ranked better than 60.9% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 3.7
vs COO: 7.10
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
The Cooper Revenue per Share Related Terms
The Cooper Revenue per Share Historical Data
* Premium members only.
The historical data trend for The Cooper's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs BAX, SOLV, ALGN: Revenue per Share Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's PS Ratio distribution charts can be found below:
* The bar in red indicates where The Cooper's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
The Cooper's Revenue Per Share for the fiscal year that ended in Oct. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (COO) has a Revenue per Share of $21.43 as of Apr. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on The Cooper and its competitors. According to the industry distribution chart, The Cooper ranks #296 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 39.1%.
Is The Cooper's Revenue per Share too high?
The Cooper's current Revenue per Share is $21.43. The Medical Devices & Instruments industry median Revenue per Share is 3.70. The Cooper's value of $21.43 is 479.2% above this industry median. Based on the distribution chart, The Cooper ranks #296 out of 757 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Revenue per Share compare to BAX and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #296 out of 757 companies for Revenue per Share. This puts The Cooper in the upper half of its industry. The industry median Revenue per Share is 3.70. The Cooper's value of $21.43 is 479.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.70, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current Revenue per Share of $21.43 is 479.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Revenue per Share is $21.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $102.02, compared to a current price of $70.27 — trading 31.1% below its estimated fair value. The current Revenue per Share is $21.43 and 479.2% above the Medical Devices & Instruments industry median of 3.70. The Cooper's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For The Cooper (COO), the current Revenue per Share is $21.43 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $70.27 is trading 31.1% below its estimated GF Value™ of $102.02.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
Revenue per Share: $21.43
GF Value™: $102.02 vs. price of $70.27 (31.1% below fair value)
Industry Position: 479.2% above the Medical Devices & Instruments median (#296 of 757)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
86GF Score
Get the complete analysis for COO
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
